Successful Treatment of a Patient with Glioblastoma and a Germline POLE Mutation: Where Next?

Cancer Discov. 2016 Nov;6(11):1210-1211. doi: 10.1158/2159-8290.CD-16-1056.

Abstract

Hypermutation and elevated neoantigen count in glioblastoma occurred in a patient harboring a germline POLE mutation and are associated with a clinical and antitumor immune response to PD-1 blockade. Cancer Discov; 6(11); 1210-11. ©2016 AACR.See related article by Johanns et al., p. 1230.

Publication types

  • Case Reports
  • Comment

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • DNA Polymerase II / genetics*
  • Gene Expression Regulation, Neoplastic / drug effects
  • Germ-Line Mutation / genetics
  • Glioblastoma / drug therapy*
  • Glioblastoma / genetics*
  • Glioblastoma / pathology
  • Humans
  • Male
  • Neoplasm Proteins / biosynthesis
  • Poly-ADP-Ribose Binding Proteins
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Programmed Cell Death 1 Receptor / genetics*

Substances

  • Antibodies, Monoclonal, Humanized
  • Neoplasm Proteins
  • PDCD1 protein, human
  • Poly-ADP-Ribose Binding Proteins
  • Programmed Cell Death 1 Receptor
  • pembrolizumab
  • DNA Polymerase II
  • POLE protein, human